Wu, XiShen, FeiJiang, GuanglongXue, GloriaPhilips, SantoshGardner, LauraCunningham, GenevaBales, CaseyCantor, EricaSchneider, Bryan Paul2023-09-252023-09-252022-11-22Wu X, Shen F, Jiang G, et al. A non-coding GWAS variant impacts anthracycline-induced cardiotoxic phenotypes in human iPSC-derived cardiomyocytes. Nat Commun. 2022;13(1):7171. Published 2022 Nov 22. doi:10.1038/s41467-022-34917-yhttps://hdl.handle.net/1805/35743Anthracyclines, widely used to treat breast cancer, have the potential for cardiotoxicity. We have previously identified and validated a germline single nucleotide polymorphism, rs28714259, associated with an increased risk of anthracycline-induced heart failure. We now provide insights into the mechanism by which rs28714259 might confer increased risk of cardiac damage. Using hiPSC-derived cardiomyocyte cell lines with either intrinsic polymorphism or CRISPR-Cas9-mediated deletion of rs28714259 locus, we demonstrate that glucocorticoid receptor signaling activated by dexamethasone pretreatment prior to doxorubicin exposure preserves cardiomyocyte viability and contractility in cardiomyocytes containing the major allele. Homozygous loss of the rs28714259 major allele diminishes dexamethasone’s protective effect. We further demonstrate that the risk allele of rs28714259 disrupts glucocorticoid receptor and rs28714259 binding affinity. Finally, we highlight the activation of genes and pathways involved in cardiac hypertrophy signaling that are blocked by the risk allele, suggesting a decreased adaptive survival response to doxorubicin-related stress.en-USAttribution 4.0 InternationalCardiovascular geneticsGene regulationMechanisms of diseaseTranscriptomicsArticle